TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30542798

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study: 29934056

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg twice daily, orally)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Vancomycin (125 mg four-times daily, orally)
Number of subjects: 212
Study: 27582448

Group type: EXPERIMENTAL
Intervention: Community treatment orders (CTOs)
Number of subjects: 0
Study: 24861389

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Suturing (Control)
Number of subjects: 15
Study: 22884569

Group type: EXPERIMENTAL
Intervention: Immediately Sequential Bilateral Cataract Surgery (ISBCS)
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Delayed Sequential Bilateral Cataract Surgery (DSBCS)
Number of subjects: 1614
Study: 19396775

Group type: EXPERIMENTAL
Intervention: Oxybiane (antioxidants combination)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17502536

Group type: EXPERIMENTAL
Intervention: Tailored print (n=86)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tailored Internet (n=81)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard Internet (n=82)
Number of subjects: 249
Study: 15309206

Group type: EXPERIMENTAL
Intervention: Angiogenic growth factors (e.g., vascular endothelial growth factors, fibroblast growth factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-blind randomized placebo controlled studies
Number of subjects: 0
Study: 11999819

Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 126

Group type: COMPARATOR
Intervention: Tensoplast
Number of subjects: 126
Study: 9627295

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.37 mg/d) for 1 year
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.37 mg/d) plus spironolactone (100 mg/d) for 1 year
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.37 mg/d) plus spironolactone (100 mg/d) for 2 years
Number of subjects: 54

Group type: COMPARATOR
Intervention: Spironolactone (100 mg/d) for 1 year
Number of subjects: 54
Study: 7946851

Group type: EXPERIMENTAL
Intervention: Training in management of malignant hyperthermia (group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Training in management of anaphylactic shock (group A)
Number of subjects: 28
Study: 3661644

Group type: EXPERIMENTAL
Intervention: Intravitreal blood (whole blood dilutions from 1/100 to 1/12,800)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravitreal blood (12.5 microliter of blood in the 5-ml test chamber)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravitreal blood (1.04 microliter of blood in the test chamber)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravitreal blood (12-fold change in concentration)
Number of subjects: 2
Study: 31935109

Group type: EXPERIMENTAL
Intervention: Mean Wingate anaerobic test (WAnTmean)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Respiratory compensation threshold (VT2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Maximal lactate steady state (MLSS)
Number of subjects: 14
Study: 29281930

Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SIT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 28822516

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 60

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 60
Study: 26420303

Group type: EXPERIMENTAL
Intervention: ForeSite PT™ system with the liquid-crystal display monitor turned on
Number of subjects: 678

Group type: COMPARATOR
Intervention: ForeSite PT™ system with monitor turned off
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 678
Study: 23717827

Group type: EXPERIMENTAL
Intervention: Self-administered (controllable) painful skin stimuli
Number of subjects: 50

Group type: COMPARATOR
Intervention: Experimenter-administered (uncontrollable) painful skin stimuli
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both controllable and uncontrollable stimuli
Number of subjects: 50
Study: 22027728

Group type: EXPERIMENTAL
Intervention: Dior PCB
Number of subjects: 57

Group type: COMPARATOR
Intervention: Taxus DES
Number of subjects: 57
Study: 18470775

Group type: EXPERIMENTAL
Intervention: 8-month family intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 92
Study: 12643887

Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 3812

Group type: COMPARATOR
Intervention: Stented Angioplasty
Number of subjects: 3812
Study: 10470982

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7784719

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD-CPR)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 6
Study: 2142013

Group type: EXPERIMENTAL
Intervention: Inhaled PAF (3-422 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo pre-medicated PAF challenge
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GR32191B (thromboxane receptor antagonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 12
Study: 644461

Group type: EXPERIMENTAL
Intervention: Chemotherapy with dimethyl triazeno imidazole carboxamide (DTIC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Immunotherapy with bacillus Calmette‐Guerin (BCG)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined chemoimmunotherapy
Number of subjects: 70
Study: 31896155

Group type: EXPERIMENTAL
Intervention: Oatmeal treatment for 2 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control treatment (T2DM-adapted diet)
Number of subjects: 15
Study: 31447123

Group type: EXPERIMENTAL
Intervention: Iontophoresis with dexamethasone (4 mg/mL) and gel lidocaine, applied on the negative electrode at 5 mA for 15 minutes.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Galvanic current with base gel solution on both electrodes.
Number of subjects: 24
Study: 28419032

Group type: EXPERIMENTAL
Intervention: Self‐directed home exercise program for 10 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard protocol for physical therapy (in-home visits for 2 weeks followed by outpatient therapy for 8 weeks)
Number of subjects: 120
Study: 25719610

Group type: EXPERIMENTAL
Intervention: high VT + ZEEP group (10-12 ml/kg PBW)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: low VT + PEEP group (6-8 ml/kg PBW with 8 cm H2O PEEP)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: low VT + PEEP + RMs group (6-8 ml/kg PBW with 8 cm H2O PEEP and recruitment maneuvers)
Number of subjects: 69

Group type: COMPARATOR
Intervention: high VT + ZEEP group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: low VT + PEEP + RMs group
Number of subjects: 69
Study: 22957802

Group type: EXPERIMENTAL
Intervention: Novel words
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Symbolic gestures
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Novel words and novel symbolic gestures
Number of subjects: 32
Study: 21810227

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (3 cycles of ECC: epirubicin, cisplatin, and capecitabine) followed by surgery and either postoperative chemotherapy (3 cycles of ECC) or concurrent chemoradiotherapy (45 Gy, cisplatin, and capecitabine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy (45 Gy, cisplatin, and capecitabine)
Number of subjects: 0
Study: 19208697

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) with a school-based intervention program based on the Theory of Planned Behaviour (TPB) for 1 year.
Number of subjects: 646

Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) with a school-based intervention program based on the TPB for 1 year.
Number of subjects: 646
Study: 17510716

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 26
Study: 15390237

Group type: EXPERIMENTAL
Intervention: AngioSeal
Number of subjects: 122

Group type: COMPARATOR
Intervention: Femostop
Number of subjects: 122
Study: 11429341

Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) at 2 L/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fresh gas flow (FGF) at 6 L/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experienced anesthesiologists (>8 yr experience)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Less experienced anesthesiologists (<2 yr experience)
Number of subjects: 16
Study: 9508190

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 and 5‐FU 1,000 mg/m2/d by continuous infusion for 96 hours (days 1 to 4) without interferon alfa-2b (arm A)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 and 5‐FU 1,000 mg/m2/d by continuous infusion for 96 hours (days 1 to 4) with interferon alfa-2b (arm B)
Number of subjects: 122
Study: 8070511

Group type: EXPERIMENTAL
Intervention: 60 micrograms of prostaglandin E1 (PGE1) administered by intravenous infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered by intravenous infusion
Number of subjects: 12
Study: 2903581

Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg orally 4 times a day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31075151

Group type: EXPERIMENTAL
Intervention: Lower barometric pressure (BMP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stress levels
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sub-group of patients (n=8)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lower BMP
Number of subjects: 48
Study: 27513367

Group type: EXPERIMENTAL
Intervention: Interferon alpha and interleukin 2
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Interferon alpha, interleukin 2, and bevacizumab
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Immunotherapy (interferon alpha and interleukin 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitors
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Immunotherapies
Number of subjects: 69
Study: 25465191

Group type: EXPERIMENTAL
Intervention: Biopsy/pre-operative chemotherapy
Number of subjects: 635

Group type: COMPARATOR
Intervention: Immediate nephrectomy
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Age, anaplasia, tumour size, lymph nodes metastases and stage
Number of subjects: 635
Study: 23356247

Group type: EXPERIMENTAL
Intervention: High-dose ω-3 fatty acid ethyl esters (3.2 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21114514

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Fluoride treatment
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Gender (Boys vs Girls)
Number of subjects: 1877
Study: 19732444

Group type: EXPERIMENTAL
Intervention: Automated Weaning (SmartCare)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Protocolized Weaning
Number of subjects: 90
Study: 17721955

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 15087963

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique for inserting a standard dynamic hip screw
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional technique for inserting a standard dynamic hip screw
Number of subjects: 0
Study: 11179537

Group type: EXPERIMENTAL
Intervention: Rhenium-188 liquid-filled balloon system
Number of subjects: 21
Study: 10079038

Group type: EXPERIMENTAL
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Number of subjects: 220
Study: 8071277

Group type: EXPERIMENTAL
Intervention: Nefazodone 100-500 mg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nefazodone 50-250 mg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Imipramine 50-250 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (2-10 capsules/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nefazodone (both dosage groups)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nefazodone and Imipramine
Number of subjects: 180
Study: 3289961

Group type: EXPERIMENTAL
Intervention: Histamine inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylcholine inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buffered saline (control)
Number of subjects: 0
Study: 31808297

Group type: EXPERIMENTAL
Intervention: Platform-switched implants (Group I)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Platform-switched implants (Group II)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Platform-matched implants (Group III)
Number of subjects: 70
Study: 30048322

Group type: EXPERIMENTAL
Intervention: Oxandrolone and Propranolol (OxProp) for 1 year
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control
Number of subjects: 480
Study: 27939652

Group type: EXPERIMENTAL
Intervention: Balance and mobility training (BMT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Balance and mobility plus cognitive training (BMT+C)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 26628263

Group type: EXPERIMENTAL
Intervention: Local anaesthetic injections (2 mL 0.5% lidocaine without a vasoconstrictor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ischemic compression via physical therapy (administered three times for 60 seconds each with 30 seconds rest)
Number of subjects: 30
Study: 23348954

Group type: EXPERIMENTAL
Intervention: 20° Trendelenburg position
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 25° Trendelenburg position
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30° Trendelenburg position
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum with head-down position in RALP
Number of subjects: 47
Study: 21445092

Group type: EXPERIMENTAL
Intervention: Degarelix (s.c., 240/80 mg, n=207)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Degarelix (s.c., 240/160 mg, n=202)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Leuprolide (i.m., 7.5 mg, n=201)
Number of subjects: 610
Study: 19004195

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at bilateral Shaoze (SI 1)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Electroacupuncture at bilateral Shangyang (LI 1)
Number of subjects: 92
Study: 16931613

Group type: EXPERIMENTAL
Intervention: Gatorade
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pedialyte
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: N-ORS
Number of subjects: 75
Study: 15625463

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-based computer-assisted surgery (CAS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 24
Study: 11028723

Group type: EXPERIMENTAL
Intervention: IT tetracaine 15 mg + neostigmine 50 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT tetracaine 15 mg + neostigmine 100 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: IT tetracaine 15 mg
Number of subjects: 60
Study: 9483407

Group type: EXPERIMENTAL
Intervention: Emoxipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hystochrom
Number of subjects: 0
Study: 8452169

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once a day for 7 days
Number of subjects: 194

Group type: COMPARATOR
Intervention: Amoxicillin 500 mg three times daily for 7 days
Number of subjects: 194
Study: 2869060

Group type: EXPERIMENTAL
Intervention: Alprazolam treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31705874

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 92
Study: 30240874

Group type: EXPERIMENTAL
Intervention: High coach support condition
Number of subjects: 356

Group type: COMPARATOR
Intervention: Low coach support condition
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Both conditions (Low and High coach support)
Number of subjects: 356
Study: 26620042

Group type: EXPERIMENTAL
Intervention: Bi‐NCPAP
Number of subjects: 132

Group type: COMPARATOR
Intervention: Re‐NCPAP
Number of subjects: 132
Study: 24446523

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg BID
Number of subjects: 0
Study: 22260745

Group type: EXPERIMENTAL
Intervention: 26% NaCl and heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0
Study: 20339636

Group type: EXPERIMENTAL
Intervention: VrHB‐IB (Instituto Butantan)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Engerix B(R) (Glaxo Smith Kline)
Number of subjects: 419
Study: 18698521

Group type: EXPERIMENTAL
Intervention: Digital noise reduction (DNR) on with 4-second onset time
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Digital noise reduction (DNR) on with 8-second onset time
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Digital noise reduction (DNR) on with 16-second onset time
Number of subjects: 25

Group type: COMPARATOR
Intervention: Digital noise reduction (DNR) off
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Digital noise reduction (DNR) on or off
Number of subjects: 25
Study: 15952999

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 1603
Study: 14598948

Group type: EXPERIMENTAL
Intervention: Profiling dialysate sodium and ultrafiltration rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard haemodialysis without profiling
Number of subjects: 0
Study: 11076326

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) supplementation (10 or 20 micrograms/kg; intravenous or nasogastric tube) for 21 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8731625

Group type: EXPERIMENTAL
Intervention: ORT with immediate modified feeding
Number of subjects: 59

Group type: COMPARATOR
Intervention: ORT alone
Number of subjects: 59
Study: 1574972

Group type: EXPERIMENTAL
Intervention: Crystalloid volume loading (10 ml.kg‐1 b.w.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no fluid loading)
Number of subjects: 90
Study: 2859650

Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (SS-28) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (SS-14) infusion at 75 pmol/kg-h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (SS-14) infusion at 500 pmol/kg-h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatostatin-28 (SS-28) compared to Somatostatin-14 (SS-14)
Number of subjects: 0
Study: 30968810

Group type: EXPERIMENTAL
Intervention: Multi-element psychosocial intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 260
Study: 29557669

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study: 26360708

Group type: EXPERIMENTAL
Intervention: Learn to BE SAFE with Emmy program (n=131)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Comparison group (n=114)
Number of subjects: 245
Study: 25467395

Group type: EXPERIMENTAL
Intervention: Overground training session
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treadmill training session
Number of subjects: 56
Study: 23057028

Group type: EXPERIMENTAL
Intervention: Electric mallet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hand mallet
Number of subjects: 80
Study: 19911168

Group type: EXPERIMENTAL
Intervention: 30 mg dose of R317573
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg dose of R317573
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17873677

Group type: EXPERIMENTAL
Intervention: 60 mg immediate-release methylphenidate (IR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 108 mg extended-release methylphenidate (osmotic release oral system [OROS])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15857282

Group type: EXPERIMENTAL
Intervention: N-chlorotaurine (1% aqueous solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gentamicin (control)
Number of subjects: 60
Study: 12221468

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy (dacarbazine, vincristine, 5‐fluorouracil, hydroxyurea)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: DTIC monotherapy or DTIC plus interferon‐alfa
Number of subjects: 224

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 224
Study: 9881560

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 105

Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 105
Study: 8003853

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 320 micrograms
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terbutaline 500 micrograms
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 160 micrograms
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 160 micrograms and 320 micrograms, Terbutaline 500 micrograms
Number of subjects: 9
Study: 2967315

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antigen challenge
Number of subjects: 0
Study: 29476530

Group type: EXPERIMENTAL
Intervention: Jaw contractions (20% maximal voluntary contraction)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: O-oris contractions (20% maximal voluntary contraction)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: O-oculi contractions (20% maximal voluntary contraction)
Number of subjects: 16
Study: 27393856

Group type: EXPERIMENTAL
Intervention: Admission temperature ≤35.5°C (hypothermia)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Admission temperature >35.5°C (control)
Number of subjects: 398